Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results.
| Autor: | Goyal K; Department of Surgery, University Hospitals-Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA., Einstein D, Yao M, Kunos C, Barton F, Singh D, Siegel C, Stulberg J, Sanabria J |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | HPB surgery : a world journal of hepatic, pancreatic and biliary surgery [HPB Surg] 2010; Vol. 2010. Date of Electronic Publication: 2010 Jun 28. |
| DOI: | 10.1155/2010/309780 |
| Abstrakt: | Purpose: Stereotactic body radiation therapy (SBRT) has emerged as a treatment option for local tumor control of primary and secondary malignancies of the liver. We report on our updated experience with SBRT in patients with non-resectable tumors of the liver. Methods: Our first 17 consecutive patients (mean age 58.1 years) receiving SBRT for HCC (n = 6), IHC (n = 3), and LM (n = 8) are presented. Mean radiation dose was 34 Gy delivered over 1-3 fractions. Results: Treated patients had a mean decrease in maximum pretreatment tumor diameter from 6.9 +/- 4.6 cm to 5.0 +/- 2.1 cm at three months after treatment (P < .05). The mean total tumor volume reduction was 44% at six months (P < .05). 82% of all patients (14/17) achieved local control with a median follow-up of 8 months. 100% of patients with HCC (n = 6) achieved local control. Patients with surgically placed fiducial markers had no complications related to marker placement. Conclusion: Our preliminary results showed that SBRT is a safe and effective local treatment modality in selected patients with liver malignancies with minimal adverse events. Further studies are needed to define its role in the management of these malignancies. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|